Section Arrow
YMAB.NASDAQ
- Y-mAbs Therapeutics
Quotes are at least 15-min delayed:2025/06/02 10:44 EDT
Last
 4.8
+0.2 (+4.35%)
Day High 
4.8 
Prev. Close
4.6 
1-M High
5.04 
Volume 
40.33K 
Bid
4.77
Ask
4.82
Day Low
4.55 
Open
4.55 
1-M Low
3.55 
Market Cap 
208.30M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.34 
20-SMA 4.17 
50-SMA 4.42 
52-W High 16.11 
52-W Low 3.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.64/-1.04
Enterprise Value
208.49M
Balance Sheet
Book Value Per Share
1.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
87.69M
Operating Revenue Per Share
1.88
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.2123+0.0923+76.92%-- 
IRDOpus Genetics Inc1.1802+0.1857+18.67%-- 
BPMCBlueprint Medicines Corp127.91+26.56+26.21%-- 
LYRALyra Therapeutics Inc27.69+22.76+461.66%-- 
PSTVPlus Therapeutics0.34+0.0531+18.51%-- 
Quotes are at least 15-min delayed:2025/06/02 10:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.